@prefix orcid: <https://orcid.org/> .
@prefix this: <http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ> .
@prefix sub: <http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix ns2: <http://twoc-nlp-database-server-1:8555/solr/triples/select?q=> .
@prefix ns1: <https://uts.nlm.nih.gov/uts/umls/concept/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix ns3: <http://twoc-nlp-database-server-1:8555/solr/predicates/select?q=> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo .
}

sub:assertion {
  sub:assertion prov:wasGeneratedBy "S&T TWOC project version 1" .
  
  sub:version prov:value "1"^^xsd:integer .
  
  rdf:object ns1:C0013227 "drugs";
    ns1:C0021764 "interleukin";
    ns1:C0245109 "anakinra";
    ns1:C1299393 "moderate to severe";
    ns1:C1513853 "non";
    ns1:C1527200 "interleukin";
    ns1:C1533148 "cases";
    ns1:C1609165 "tocilizumab";
    ns1:C1609931 "siltuximab";
    ns1:C3687832 "drugs" .
  
  rdf:predicate ns3:TRIPLE_UID:pq34mfzt-TRIPLE-ABSTRACT-2 "be" .
  
  rdf:subject ns1:C0011777 "dexamethasone";
    ns1:C0178602 "dose";
    ns1:C0205251 "low";
    ns1:C0869039 "dose";
    ns1:C1550472 "low";
    ns1:C1611820 "low";
    ns1:C1619811 "low";
    ns1:C2700150 "low";
    ns1:C3890211 "low";
    ns1:C4048187 "low";
    ns1:C4321351 "low";
    ns1:C4522223 "low";
    ns1:C5203106 "low" .
  
  rdfs:Triple-UID ns2:TRIPLE_UID:pq34mfzt-TRIPLE-ABSTRACT-2 "pq34mfzt-TRIPLE-ABSTRACT-2" .
  
  rdfs:sentence rdfs:label "To target the inflammatory cascade, low-dose dexamethasone appears to be helpful in moderate to severe cases and trials with anti-interleukin agents (e.g., tocilizumab, anakinra, siltuximab) and non-steroidal anti-inflammatory drugs are showing early promising results." .
  
  rdfs:triple rdfs:label "low - dose dexamethasone be in moderate to severe cases and trials with anti - interleukin agents ( e.g. , tocilizumab , anakinra , siltuximab ) and non - steroidal anti - inflammatory drugs" .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2021-07-25T21:46:20.879852"^^xsd:dateTime .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB";
    npx:hasSignature "ZappbXqFom74kzqytuyy81GX87uQV1IZTWGtOc/KNsnEuF/H7ivtcu4vMTEa7vZACiqOQR+4JR/r+p7kUEfFWvfKuITyKbNp9unIQVcxtJWtoig6qr1YBejcDjHN9Wc0fHh0uDndYwgq6QM+Z+B1uwZ8z+U4eyHRdWmNau3VZmA=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2021-07-25T21:46:20.879852"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-8954-0470 .
}